



September 2022 Pharmacy & Therapeutics Committee Decisions

UCare’s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare formularies (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for the Medicare formularies are tentative until UCare receives final CMS approval.

Key:

Medicare: UCare Medicare, UCare Medicare with Fairview and North Memorial, UCare Group Medicare, EssentiaCare, Minnesota Senior Health Options (MSHO) & Connect + Medicare

Medicaid: PMAP, MnCare, MSC+ & Connect

Exchange: UCare Individual and Family Plans

F: Formulary

NF: Non-formulary

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

New Drug Review			
Drug	Indication	Formulary Coverage	Effective Date
Quviviq (daridorexant hcl)	Quviviq is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
Radicava ORS (edaravone)	treatment of amyotrophic lateral sclerosis (ALS).	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
Verkazia (cyclosporine)	the treatment of vernal keratoconjunctivitis (VKC) in patients 4 years and older	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	10/1/2022
Vijoice (alpelisib)	treatment of severe manifestations of phosphatidylinositol- 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-Related Overgrowth Spectrum (PROS) in adults and pediatric patients ≥ 2 years of age who require systemic therapy.	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	10/1/2022

September 2022 Pharmacy & Therapeutics Committee Decisions

Adlarity (donepezil hcl)	treatment of mild, moderate, and severe dementia of the Alzheimer's type	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
Camzyos (mavacamten)	symptomatic New York Heart Association (NYHA) Class II to III obstructive hypertrophic cardiomyopathy (HCM) in adults	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	10/1/2022
Mounjaro (tirzepatide)	adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	Medicare: Formulary w/PA Medicaid: Non-Formulary Exchange: Formulary w/PA	10/1/2022
Opdualag (nivolumab-relatimab-rmbw) PROTECTED CLASS	unresectable or metastatic melanoma in patients \geq 12 years of age	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary (Covered under medical benefit with PA for all plans)	N/A
Pluvicto (lu-177 vipivotide tetraxetan) PROTECTED CLASS	prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adults who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary (Covered under medical benefit with PA for all plans)	N/A
Amvuttra (vutrisiran sodium)	polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary (Covered under medical benefit with PA for all plans)	N/A

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 10/1/2022.

September 2022 Pharmacy & Therapeutics Committee Decisions

New Indications Review		
Drug	Current formulary status	Recommendation
Dupixent – EoE 12+	Medicare – F, Medicaid – P, HIX - F	Medicare – F, Medicaid –P, HIX - F
Tibsovo – acute AML	Medicare – F, Medicaid – F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Evrysdi – SMA 2mo+	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Mekinist/Tafinlar – BRAF v600 mutations in solid tumors	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Cellcept – organ rejection prophylaxis 6mo+	Medicare - F, Medicaid - P, HIX - F	Medicare - F, Medicaid - P, HIX - F
Vaxneuvance	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Olumiant – hospitalized Covid-19, alopecia areata	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Imcivree – Bardet-Biedle	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Qsymia – weight loss 12+	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Humira biosimilars – pJIRA 2+, CD 6+	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Vidaza - JMML	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Beovu – diabetic macular edema	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Riabni – RA w/MTX	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Enhertu – recurrent breast cancer	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Opdivo - ESCC	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Kymriah – follicular lymphoma	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Sulresso – PPD 15+	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Breyanzi – expanded DLBCL	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF

New Generics Review		
Drug	Current formulary status	Recommendation

September 2022 Pharmacy & Therapeutics Committee Decisions

Maraviroc 150mg + 300mg (Selzentry)	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - NF, HIX - F
Deferiprone 1g (Ferriprox)	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Lenalidomide (Revlimid)	Medicare - F, Medicaid - F, HIX - F	Medicare - NF, Medicaid - F, HIX - F
Pirfenidone (Esbriet)	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Varenicline starter pack (Chantix)	Medicare - NF, Medicaid - NF, HIX - NF	Medicare - F, Medicaid - F, HIX - F
Mesalamine ER 500mg (Pentasa)	Medicare - F, Medicaid - P, HIX - F	Medicare - F, Medicaid - NF, HIX - NF
Bexarotene gel (Targretin)	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F

Miscellaneous Previously Reviewed Items

Drug	Rationale/Alternative	Recommendation
Camcevi (Leuprolide) syringe	Eligard, Firmagon, Lupron Depot, Orgovyx, Trelstar	NF all lines of business
Valsartan Soln	Valsartan tablet	NF all lines of business
Paclitaxel Vial	Medical drug	NF all lines of business
Insulin glargine	Lantus, Levemir	NF all lines of business
Norliqva (amlodipine) soln	Amlodipine tablet	NF all lines of business
Tlando (testosterone) capsule	Androderm, testosterone cypioate	NF all lines of business
Levamlodipine tablet	Amlodipine tablet, felodipine ER, nifedipine ER	NF all lines of business
Anzemet (Dolasetron) tablet	Ondansetron, granisetron	NF all lines of business
Fluticasone HFA	Clinical guidelines	F - Medicare - Formulary HIX, Medicaid - Non-Formulary
Fluticasone-vilanterol inhaler	Breo Ellipta	NF all lines of business
One Touch Solutions	Digital solution, not test strips	NF all lines of business
Bortezomib vial	Medical drug	NF all lines of business
Alymsys (bevacizumab) vial	Medical drug	NF all lines of business
Lyvispah (baclofen) granules	Baclofen tablet	NF all lines of business
Metformin 625mg tablet	Metformin 500mg, 750mg, 1000mg	NF all lines of business

September 2022 Pharmacy & Therapeutics Committee Decisions

Additional Items Reviewed	
Item	Action
New Medical Drug Policies	<ul style="list-style-type: none">• Amuttraa – policy effective 11/15/22• Skyrizi - policy effective 11/15/22• Nplate – policy effective 1/1/23
Diabetic Product Review	<ul style="list-style-type: none">• CeQur – non-formulary (will revisit in 3-6 months)• Eversense E3 CGM – covered under medical benefit. Non-formulary on pharmacy benefit.• Freestyle Libre 3 – added to formulary for all lines of business